利妥昔单抗联合多柔比星脂质体治疗复发难治性非霍奇金淋巴瘤的疗效观察
|
摘要
目的探讨利妥昔单抗注射液联合多柔比星脂质体治疗复发难治性非霍奇金淋巴瘤的临床疗效和不良反应。方法选取2014年1月—2015年1月沧州市中心医院收治的复发难治性非霍奇金淋巴瘤患者60例为研究对象,所有患者随机分为对照组和治疗组,每组各30例。对照组静脉滴注盐酸多柔比星脂质体注射液,20 mg/m~2,1次/2周。治疗组在对照组的基础上静脉滴注利妥昔单抗注射液375 mg/m~2,1次/周。两组患者均连续治疗6周。观察两组的临床疗效,比较两组的无进展生存期(PFS)、总生存期(OS)和患者Karnofsky(KPS)评分。结果治疗后,对照组和治疗组的总有效率分别为36.67%、66.67%,疾病控制率分别为56.67%、80.00%,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组PFS、OS和KPS评分均显著高于对照组,两组比较差异有统计学意义(P<0.05)。治疗组发生白细胞计数降低、贫血的例数显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论利妥昔单抗注射液联合多柔比星脂质体治疗复发难治性非霍奇金淋巴瘤具有较好的临床疗效,可延长患者生存时间,改善生活质量,安全性较好,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Rituximab Injection combined with Doxorubicin Hydrochloride Liposome Injection in treatment of relapsed or refractory non-Hodgkin’s lymphoma.Methods Patients(60 cases)with cerebral infarction in Cangzhou Central Hospital from January 2014 to January 2015 were randomly divided into control and treatment groups,and each group had 30 cases.Patients in the control group were iv administered with Doxorubicin Hydrochloride Liposome Injection,20mg/m~2,once weekly.Patients in the treatment group were iv administered with Rituximab Injection on the basis of the control group,375 mg/m~2,once every two weeks.Patients in two groups were treated for 6 weeks.After treatment,the clinical efficacies were evaluated,and PFS,OS,KPS scores in two groups were compared.Results After treatment,the clinical efficacies in the control and treatment groups were 36.67%and 66.67%,respectively,and the disease control rates in the control and treatment groups were56.67%and 80.00%,respectively,and there was difference between two groups(P<0.05).After treatment,PFS,OS,KPS scores in the treatment group were significantly higher than those in the control group,and there was difference between two groups(P<0.05).The number of white blood cell count and anemia in the treatment group were significantly lower than those in the control group,and there was difference between two groups(P<0.05).Conclusion Rituximab Injection combined with Doxorubicin Hydrochloride Liposome Injection has clinical curative effect in treatment of relapsed or refractory non-Hodgkin’s lymphoma,can prolong survival time and improve quality of life,with good safety,which has a certain clinical application value.
Objective To investigate the clinical effect of Rituximab Injection combined with Doxorubicin Hydrochloride Liposome Injection in treatment of relapsed or refractory non-Hodgkin’s lymphoma.Methods Patients(60 cases)with cerebral infarction in Cangzhou Central Hospital from January 2014 to January 2015 were randomly divided into control and treatment groups,and each group had 30 cases.Patients in the control group were iv administered with Doxorubicin Hydrochloride Liposome Injection,20mg/m~2,once weekly.Patients in the treatment group were iv administered with Rituximab Injection on the basis of the control group,375 mg/m~2,once every two weeks.Patients in two groups were treated for 6 weeks.After treatment,the clinical efficacies were evaluated,and PFS,OS,KPS scores in two groups were compared.Results After treatment,the clinical efficacies in the control and treatment groups were 36.67%and 66.67%,respectively,and the disease control rates in the control and treatment groups were56.67%and 80.00%,respectively,and there was difference between two groups(P<0.05).After treatment,PFS,OS,KPS scores in the treatment group were significantly higher than those in the control group,and there was difference between two groups(P<0.05).The number of white blood cell count and anemia in the treatment group were significantly lower than those in the control group,and there was difference between two groups(P<0.05).Conclusion Rituximab Injection combined with Doxorubicin Hydrochloride Liposome Injection has clinical curative effect in treatment of relapsed or refractory non-Hodgkin’s lymphoma,can prolong survival time and improve quality of life,with good safety,which has a certain clinical application value.
引文
[1]石远凯,于燕霞.非霍奇金淋巴瘤治疗进展[J].临床肿瘤学杂志,2006,11(7):481-485.
[2]徐吉兵,王季石,惠阳.难治性非霍奇金淋巴瘤的治疗进展[J].中西医结合研究,2012,4(3):160-162.
[3]吴昊.利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的临床疗效分析[J].中国社区医师,2016,32(33):71-72.
[4]尹青松袁芳芳熊媛媛,等.来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察[J].中华血液学杂志,2017,38(7):634-636.
[5]Nguyen J,Solimando D A Jr,Waddell J A.Carboplatin and Liposomal Doxorubicin for Ovarian Cancer[J].Hosp Pharm,2016,51(6):442-449.
[6]谢雨礼,苏红.抗肿瘤药物多柔比星脂质体[J].药学与临床研究,2010,18(2):107-111.
[7]苗雨青,徐浩,李建勇,等.2015年第2版美国国立综合癌症网络(NCCN)非霍奇金淋巴瘤诊疗指南Castleman病解读[J].白血病.淋巴瘤,2015,24(10):628-631.
[8]Palmer M K.WHO Handbook for Reporting Results of Cancer Treatment[M].WHO Offset Publication No.48.WHO,1979.
[9]Friendlander A H,Ettinger R L.Karnofsky performance status scale[J].Spec Care Dentist,2009,29(4):147-148.
[10]陈杏梅,覃艳琼,万里鹏.利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效分析[J].癌症进展,2016,14(5):486-488.
[11]王潇潇,黄慧强,夏忠军,等.利妥昔单抗联合挽救化疗治疗复发或难治弥漫大B细胞性非霍奇金淋巴瘤的长期随访结果[J].南方医科大学学报,2010,30(4):867-870.
[12]陈永升,孔佩艳,曾东风,等.利妥昔单抗免疫化疗联合自体外周血干细胞移植治疗CD20+B细胞性非霍奇金淋巴瘤的临床研究[J].解放军医学杂志,2013,38(7):591-596.
[13]桂琳,石远凯,杨建良,等.含聚乙二醇脂质体多柔比星的CHOP样方案治疗初治老年晚期弥漫大B细胞淋巴瘤的Ⅱ期临床研究[J].中国肿瘤临床,2015,42(3):162-166.
[2]徐吉兵,王季石,惠阳.难治性非霍奇金淋巴瘤的治疗进展[J].中西医结合研究,2012,4(3):160-162.
[3]吴昊.利妥昔单抗联合化疗治疗非霍奇金淋巴瘤的临床疗效分析[J].中国社区医师,2016,32(33):71-72.
[4]尹青松袁芳芳熊媛媛,等.来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察[J].中华血液学杂志,2017,38(7):634-636.
[5]Nguyen J,Solimando D A Jr,Waddell J A.Carboplatin and Liposomal Doxorubicin for Ovarian Cancer[J].Hosp Pharm,2016,51(6):442-449.
[6]谢雨礼,苏红.抗肿瘤药物多柔比星脂质体[J].药学与临床研究,2010,18(2):107-111.
[7]苗雨青,徐浩,李建勇,等.2015年第2版美国国立综合癌症网络(NCCN)非霍奇金淋巴瘤诊疗指南Castleman病解读[J].白血病.淋巴瘤,2015,24(10):628-631.
[8]Palmer M K.WHO Handbook for Reporting Results of Cancer Treatment[M].WHO Offset Publication No.48.WHO,1979.
[9]Friendlander A H,Ettinger R L.Karnofsky performance status scale[J].Spec Care Dentist,2009,29(4):147-148.
[10]陈杏梅,覃艳琼,万里鹏.利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效分析[J].癌症进展,2016,14(5):486-488.
[11]王潇潇,黄慧强,夏忠军,等.利妥昔单抗联合挽救化疗治疗复发或难治弥漫大B细胞性非霍奇金淋巴瘤的长期随访结果[J].南方医科大学学报,2010,30(4):867-870.
[12]陈永升,孔佩艳,曾东风,等.利妥昔单抗免疫化疗联合自体外周血干细胞移植治疗CD20+B细胞性非霍奇金淋巴瘤的临床研究[J].解放军医学杂志,2013,38(7):591-596.
[13]桂琳,石远凯,杨建良,等.含聚乙二醇脂质体多柔比星的CHOP样方案治疗初治老年晚期弥漫大B细胞淋巴瘤的Ⅱ期临床研究[J].中国肿瘤临床,2015,42(3):162-166.